


Memorial Sloan Kettering ASCO Meeting Abstracts 2016

Another ASCO meeting has come and gone and MSK continues to make our mark at the conference. Contributing a total of 304 abstracts this year, MSK stands at a 3% increase over the number of abstracts that were presented at the 2015 Annual Meeting (296 abstracts).

As was done in [2014](#) and [2015](#), we determined the number of MSK researchers who presented 10 or more abstracts at the meeting. Here are the nine MSK researchers who meet this criteria - up from 2014's seven and down from 2015's 12 MSK authors with 10 or more abstracts at ASCO:

- [M.F. Berger](#) (19)
- [D.B. Solit](#) (17)
- [R.J. Motzer](#) (15)
- [J.D. Wolchok](#) (13)
- [D.M. Hyman](#) (13)
- [J.T. Baselga](#) (13)
- [J.E. Rosenberg](#) (11)
- [E.M. O'Reilly](#) (11)
- [C.A. Hudis](#) (11)



Memorial Sloan Kettering ASCO Meeting Abstracts 2016

1. Abou-Alfa GK, Galle PR, Chao Y, Brown KT, Heo J, Borad MJ, et al. PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS4146.
2. Abou-Alfa GK, Niedzwieski D, Knox JJ, Kaubisch A, Posey J, Tan BR, et al. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). ASCO Meeting Abstracts. 2016;34(15_suppl):4003.
3. Abou-Alfa GK, Qin S, Ryoo B-Y, Lu S-N, Yen C-J, Feng Y-H, et al. Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC). ASCO Meeting Abstracts. 2016;34(15_suppl):4017.
4. Abou-Alfa GK, Sangro B, Morse M, Zhu AX, Kim RD, Cheng A-L, et al. Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC). ASCO Meeting Abstracts. 2016;34(15_suppl):TPS3103.
5. Abu Zaid MI, Fung C, Williams A, Sesso HD, Kerns SL, Ardeshir-Rouhani-Fard S, et al. Cardiovascular disease (CVD) risk factors and health behaviors after cisplatin-based chemotherapy (CHEM): A multi-institutional study of testicular cancer survivors (TCS) in the Platinum study. ASCO Meeting Abstracts. 2016;34(15_suppl):10087.
6. Adrianzen Herrera DA, Kuk D, Keohan ML, Dickson MA, D'Angelo SP, Chi P, et al. Outcomes of systemic therapy for patients with metastatic undifferentiated pleomorphic sarcoma (UPS). ASCO Meeting Abstracts. 2016;34(15_suppl):11066.
7. Agulnik M, Tannir NM, Pressey JG, Gounder MM, Cote GM, Roche M, et al. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS11071.
8. Aisner D, Sholl LM, Berry LD, Haura EB, Ramalingam SS, Glisson BS, et al. Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience. ASCO Meeting Abstracts. 2016;34(15_suppl):11510.
9. Anand A, Daignault S, Nordquist LT, Ramos J, Jain RK, McDonald M, et al. Automated bone scan index as an imaging biomarker in metastatic castration resistant prostate cancer (mCRPC) patients treated with radium-223. ASCO Meeting Abstracts. 2016;34(15_suppl):e16600.
10. Antonia SJ, Kim S-W, Spira AI, Ahn M-J, Ou S-HI, Stjepanovic N, et al. Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non-small-cell lung cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):9029.
11. Armand P, Brody J, Barr PM, Shustov AR, Moskowitz AJ, Kline JP, et al. A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs). ASCO Meeting Abstracts. 2016;34(15_suppl):TPS7576.
12. Armstrong AJ, Saad F, Shore ND, Fizazi K, Phung D, Dmuchowski C, et al. Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM. ASCO Meeting Abstracts. 2016;34(15_suppl):5062.
13. Bajorin DF, Sharma P, Quinn DI, Plimack ER, Hoffman-Censits JH, O'Donnell PH, et al. Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts). ASCO Meeting Abstracts. 2016;34(15_suppl):4513.
14. Balar AV, Galsky MD, Loriot Y, Dawson NA, Necchi A, Srinivas S, et al. Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1. ASCO Meeting Abstracts. 2016;34(15_suppl):LBA4500.

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

15. Balmana J, Digiovanni L, Gaddam P, Walsh MF, Garber JE, Couch FJ, et al. Identification of genetic test results with conflicting interpretations in prospective registry of multiplex testing (PROMPT). ASCO Meeting Abstracts. 2016;34(15_suppl):1510.
16. Bao T, Li SQ, Mao JJ. Prevalence, risk factors, and sequelae of long-term chemotherapy-induced peripheral neuropathy (CIPN) among breast cancer survivors. ASCO Meeting Abstracts. 2016;34(15_suppl):e21661.
17. Bardia A, Dacosta NA, Gabrail NY, Lemon S, Danso MA, Ali HY, et al. Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC). ASCO Meeting Abstracts. 2016;34(15_suppl):1088.
18. Barrientos JC, Brown JR, Atallah EL, Coutre S, De La Serna J, Eradat HA, et al. Results of a randomized, double-blind placebo-controlled phase 3 study evaluating idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL and adverse prognostic features. ASCO Meeting Abstracts. 2016;34(15_suppl):7514.
19. Baselga J, Cortes J, De Laurentiis M, Dieras V, Harbeck N, Hsu JY, et al. SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS617.
20. Baumgartner JM, Banks KC, Lanman RB, Tran L, Kelly KJ, Lowy AM, et al. Circulating tumor DNA before and after surgical resection in patients with peritoneal carcinomatosis. ASCO Meeting Abstracts. 2016;34(15_suppl):e13000.
21. Bauml J, Seiwert TY, Pfister DG, Worden FP, Liu SV, Gilbert J, et al. Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC). ASCO Meeting Abstracts. 2016;34(15_suppl):6011.
22. Baxi SS, Jones L, Eaton A, Gandelman S, Halpenny D, Jackson J, et al. Changes in body composition and prognostic importance of sarcopenia in patients receiving CRT for oropharyngeal cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):6077.
23. Baxi SS, Kale M, Roman BR, Yang A, Derosa A, Kim A, et al. Systematic review of overuse in oncology. ASCO Meeting Abstracts. 2016;34(15_suppl):e18257.
24. Bendell JC, Kim TW, Goh BC, Wallin J, Oh D-Y, Han S-W, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). ASCO Meeting Abstracts. 2016;34(15_suppl):3502.
25. Bentley TGK, Cohen JT, Elkin EB, Huynh J, Mukherjee A, Neville T, et al. Reliability and consistency of three value frameworks for oncology therapeutics. ASCO Meeting Abstracts. 2016;34(15_suppl):e18250.
26. Berlin J, Posadas EM, Macarulla TM, Cacovean A, Eckert K, Munneke B, et al. A phase 1b/2 study of ibrutinib combination therapy in selected advanced genitourinary and gastrointestinal tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS2600.
27. Blinder VS, Eberle CE, Patil S, Oeffinger KC, Bradley C, Gany F. Correlates of work status during adjuvant chemo- or radiation therapy for breast cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):6556.
28. Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE, Jacobs SA, et al. Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):1000.

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

29. Borghaei H, Brahmer JR, Horn L, Ready N, Steins M, Felip E, et al. Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. ASCO Meeting Abstracts. 2016;34(15_suppl):9025.
30. Braghiroli MIFM, Nash GM, Morris M, Hechtman JF, Vakiani E, Berger MF, et al. Genomic profiling and efficacy of anti-EGFR therapy in appendiceal adenocarcinoma. ASCO Meeting Abstracts. 2016;34(15_suppl):4102.
31. Brewster AM, Peterson SK, Bedrosian I, Dong W, Cantor SB, Volk RJ, et al. Psychosocial predictors of decision making for contralateral prophylactic mastectomy. ASCO Meeting Abstracts. 2016;34(15_suppl):6581.
32. Burger RA, Deng W, Makker V, Lankes HA, Aghajanian C, Gray HJ, et al. PHASE II evaluation of dalantercept for persistent or recurrent epithelial ovarian and related cancers: An NRG oncology study. ASCO Meeting Abstracts. 2016;34(15_suppl):e17050.
33. Cadoo KA, Tran C, DeLair D, Arnold AG, Ashraf A, Jewell EL, et al. Clinical characterization of DNA mismatch repair deficiency (MMR-D) in endometrial cancer (EC). ASCO Meeting Abstracts. 2016;34(15_suppl):1522.
34. Carlo MI, Chen Y, Chaim J, Coskey DT, Woo K, Hsieh J, et al. Medullary renal cell carcinoma (RCC): Genomics and treatment outcomes. ASCO Meeting Abstracts. 2016;34(15_suppl):4556.
35. Cassidy MR, Wolchok R, Zheng J, Panageas K, Wolchok JD, Coit DG, et al. Neutrophil to lymphocyte ratio to predict outcome during ipilimumab treatment. ASCO Meeting Abstracts. 2016;34(15_suppl):e21008.
36. Cella D, Gruenwald V, Nathan PD, Doan J, Dastani H, Taylor F, et al. Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study. ASCO Meeting Abstracts. 2016;34(15_suppl):4549.
37. Chakravarty D, Phillips SM, Gao J, Kundra R, Zhang H, Rudolph JE, et al. OncoKB: Annotation of the oncogenic effect and treatment implications of somatic mutations in cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):11583.
38. Chapman PB, Sznol M, Lao C, Gonzalez R, Daniels GA, Thompson JA, et al. Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL). ASCO Meeting Abstracts. 2016;34(15_suppl):9525.
39. Chen RW, Jacobsen ED, Kostic A, Liu T, Moskowitz CH. A randomized, phase 2 trial of denintuzumab mafodotin and RICE vs RICE alone in the treatment of patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant (ASCT). ASCO Meeting Abstracts. 2016;34(15_suppl):TPS7584.
40. Chen RW, Zinzani PL, Fanale MA, Armand P, Johnson N, Ribrag V, et al. Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. ASCO Meeting Abstracts. 2016;34(15_suppl):7555.
41. Chera BS, Gupta GP, Weiss J, Grilley-Olson JE, Moore DT, Zevallos J, et al. Phase Ib trial of dose-escalating AZD1775 in combination with concurrent radiation and cisplatin for intermediate and high risk head and neck squamous cell carcinoma. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS6106.
42. Chiang AC, Rudin CM, Spira AI, Jotte RM, Gadgeel SM, Mita AC, et al. Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). ASCO Meeting Abstracts. 2016;34(15_suppl):8564.
43. Choueiri TK, Powles T, Escudier BJ, Tannir NM, Mainwaring P, Rini BI, et al. Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC). ASCO Meeting Abstracts. 2016;34(15_suppl):4506.

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

44. Chow S, Pillai MR, Galvis V, Leach R, Keene E, Chan K, et al. 10 year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC). ASCO Meeting Abstracts. 2016;34(15_suppl):e16085.
45. Cirkel GA, Hamberg P, Sleijfer S, Loosveld O, Dercksen W, Los M, et al. A randomized phase II study to compare the efficacy of upfront bi-monthly rotations between pazopanib (PAZ) and everolimus (EVE) versus sequential treatment of first-line PAZ and second-line EVE until progression in patients with metastatic clear cell renal cell cancer (ccRCC) (ROPETAR trial). ASCO Meeting Abstracts. 2016;34(15_suppl):4550.
46. Coleman RL, Brady MF, Herzog TJ, Armstrong DK, Sabbatini P, Walker JL, et al. Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213. ASCO Meeting Abstracts. 2016;34(15_suppl):5523.
47. Coleman RL, Swisher EM, Oza AM, Scott CL, Giordano H, Lin KK, et al. Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC). ASCO Meeting Abstracts. 2016;34(15_suppl):5540.
48. Connell LC, Sanchez-Vega F, Boucher TM, Yaeger RD, Schultz N, Cercek A, et al. Correlation between comprehensive molecular profiling and clinical outcomes in patients with colorectal liver metastases. ASCO Meeting Abstracts. 2016;34(15_suppl):e15114.
49. Copur MS, Bigley S, Frey N, Gonen M, Hadenfeldt R, Gulzow M, et al. Obesity and breast cancer: Analysis of Breast Cancer Collaborative Registry (BCCR) data in a rural community cancer center. ASCO Meeting Abstracts. 2016;34(15_suppl):e13103.
50. Copur MS, Gnewuch C, Schrinier M, Gonen M, McDonald M, Kezeor J, et al. Potential cost savings by dose rounding monoclonal antibodies (mAB) in a community cancer center. ASCO Meeting Abstracts. 2016;34(15_suppl):6616.
51. Danila DC, Kuzel T, Cetnar JP, Rathkopf DE, Morris MJ, Alumkal JJ, et al. A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naive patients with progressive metastatic castration resistant prostate cancer (mCRPC). ASCO Meeting Abstracts. 2016;34(15_suppl):e16507.
52. Danila DC, Thomas S, Rajpurohit YR, Herkal A, Gormley M, Dayan ES, et al. Prostate cancer enhanced mRNA detection assay in whole blood as predictive biomarker of tumor sensitivity to targeted androgen inhibition for men with metastatic castration-resistant prostate cancer (mCRPC). ASCO Meeting Abstracts. 2016;34(15_suppl):5038.
53. Davids MS, Gerecitano JF, Potluri J, Cerri E, Kim SY, Steinberg M, et al. Integrated safety analysis of venetoclax monotherapy in chronic lymphocytic leukemia (CLL). ASCO Meeting Abstracts. 2016;34(15_suppl):7528.
54. Davids MS, Roberts AW, Seymour JF, Gerecitano JF, Kahl BS, Kipps TJ, et al. Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL). ASCO Meeting Abstracts. 2016;34(15_suppl):7527.
55. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze S, Elias AD, et al. Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS). ASCO Meeting Abstracts. 2016;34(15_suppl):11061.
56. DeMichele A, Harding JJ, Telli ML, Munster PN, McKay R, Iliopoulos O, et al. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC). ASCO Meeting Abstracts. 2016;34(15_suppl):1011.
57. Derosa L, Bayar MA, Albiges L, Massard C, Lorient Y, Fizazi K, et al. A new prognostic model of survival in second-line targeted therapy (TT) for metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts. 2016;34(15_suppl):e16113.
58. Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, et al. A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

(HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC). ASCO Meeting Abstracts. 2016;34(15_suppl):520.

59. Dickler MN, Tolaney SM, Rugo HS, Cortes J, Dieras V, Patt DA, et al. MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2-breast cancer, after chemotherapy for advanced disease. ASCO Meeting Abstracts.

2016;34(15_suppl):510.

60. Dobrenkov K, Ostrovnaya I, Cheung IY, Feng Y, Cheung N-KV. GD2/GD3 expression: Companion diagnostic for ganglioside-targeted immunotherapy against pediatric solid tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):10567.

61. Drilon AE, Camidge DR, Ou S-HI, Clark JW, Socinski MA, Weiss J, et al. Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2016;34(15_suppl):108.

62. Drilon AE, Hong DS, Cruickshank S, Deegan M, Ku N, Hyman DM. A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Adult Subjects with NTRK Fusion-Positive Tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS2599.

63. Dunn L, Sherman EJ, Baxi SS, Grewal RK, Pentlow KS, Haque S, et al. Enhancing radioiodine (RAI) incorporation into BRAFV600E-mutant, RAI-refractory thyroid cancers with the BRAF inhibitor vemurafenib: A pilot study. ASCO Meeting Abstracts. 2016;34(15_suppl):6099.

64. Eads JR, Catalano PJ, Fisher GA, Klimstra DS, Zhang Z, Rubin D, et al. Randomized phase II study of cisplatin and etoposide versus temozolomide and capecitabine in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas (GEPNEC): A trial of the ECOG-ACRIN Cancer Research Group (EA2142). ASCO Meeting Abstracts. 2016;34(15_suppl):TPS4149.

65. El Charif O, Wheeler HE, Mushiroda T, Kubo M, Gamazon ER, Feldman DR, et al. Genome-wide association study of cisplatin-induced peripheral neuropathy (CIPN) in testicular cancer survivors. ASCO Meeting Abstracts. 2016;34(15_suppl):4543.

66. Emile J-F, Cohen-Aubart F, Baillou C, Roos-Weil D, Papo M, Helias-Rodzewicz Z, et al. Recurrent BRAF mutations in bone marrow progenitors of patients with Erdheim-Chester disease. ASCO Meeting Abstracts. 2016;34(15_suppl):7069.

67. Epstein AS, Yang A, Colbert L, Voigt L, Meadows J, Goldberg J, et al. Outcomes of ICU admission of patients with progressive metastatic gastrointestinal (GI) cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):e18124.

68. Escudier BJ, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, et al. Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study. ASCO Meeting Abstracts. 2016;34(15_suppl):4509.

69. Escudier BJ, Powles T, Motzer RJ, Olencki T, Aren OR, Oudard S, et al. Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study. ASCO Meeting Abstracts. 2016;34(15_suppl):4558.

70. Fakhry C, Zhang Q, Gillison ML, Nguyen PD, Rosenthal DI, Weber RS, et al. Predicting overall survival (OS) and progression-free (PFS) for oropharynx cancers (OPC) in NRG Oncology RTOG0129/0522 with nomograms. ASCO Meeting Abstracts. 2016;34(15_suppl):6024.

71. Feldman DR, Ardeshir-Rouhani-Fard S, Monahan P, Fung C, Hamilton RJ, Vaughn DJ, et al. Estimation of 10-year (y) cardiovascular disease (CVD) risk after cisplatin-based chemotherapy (CBCT): A multi-institutional study of 459 germ cell tumor (GCT) survivors in the Platinum study. ASCO Meeting Abstracts. 2016;34(15_suppl):10083.

72. Forde PM, Smith K, Chaft JE, Hellmann MD, Merghoub T, Wolchok JD, et al. Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):e20005.

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

73. Freedman RA, Polley M-Y, Dueck AC, Hurria A, Muss HB, Ruddy KJ, et al. Academic and Community Cancer Research United (ACCRU) RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS629.
74. Freedman RA, Seisler DK, Foster JC, Lafky JM, Kimmick GG, Jatoi A, et al. Accrual of older patients (pts) with breast cancer to Alliance systemic therapy trials over time: A151527. ASCO Meeting Abstracts. 2016;34(15_suppl):1024.
75. Friedman CF, Horvat TZ, Minehart J, Panageas K, Callahan MK, Chapman PB, et al. Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+). ASCO Meeting Abstracts. 2016;34(15_suppl):10009.
76. Friedman CF, Navid-Azarbaijani P, Shoushtari AN, Campbell SC, Callahan MK, Momtaz P, et al. Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP). ASCO Meeting Abstracts. 2016;34(15_suppl):9519.
77. Funt S, Snyder Charen A, Yusko E, Vignali M, Benzeno S, Boyd ME, et al. Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (mUC) treated with atezolizumab. ASCO Meeting Abstracts. 2016;34(15_suppl):3005.
78. Gallagher E, Leroith D, Feldman SM, Port ER, Friedman N, Pilewskie ML, et al. Are racial differences in obesity and insulin resistance related to aggressive breast cancer? ASCO Meeting Abstracts. 2016;34(15_suppl):1568.
79. Gamazon ER, Wheeler HE, Frisina RD, El Charif O, Mushiroda T, Kubo M, et al. Variation in protein-coding sequence and the genetic basis of cisplatin-induced toxicities among testicular cancer survivors (TCS) in the Platinum Study. ASCO Meeting Abstracts. 2016;34(15_suppl):1537.
80. Ganesh K, Middha S, Hechtman JF, Ashraf A, Tran C, Villano D, et al. Somatic tumor profiling of DNA mismatch repair deficient (MMR-D) colorectal cancers (CRC). ASCO Meeting Abstracts. 2016;34(15_suppl):1528.
81. Gautschi O, Wolf J, Milia J, Filleron T, Carbone DP, Camidge DR, et al. Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry. ASCO Meeting Abstracts. 2016;34(15_suppl):9014.
82. Gavane SC, Ito K, Moskowitz CH, Moskowitz AJ, Schoder H. Metabolic tumor volume to predict event free survival in patients with relapsed/refractory HL treated with brentuximab vedotin-based salvage therapy. ASCO Meeting Abstracts. 2016;34(15_suppl):11566.
83. Geyer MB, Hsu M, Devlin S, Douer D, Park JH. Outcomes of patients 60 and older with ALL: Analysis of the SEER Database. ASCO Meeting Abstracts. 2016;34(15_suppl):7021.
84. Geyer MB, Park JH, Riviere I, Wang X, Purdon T, Sadelain M, et al. Updated results: phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy. ASCO Meeting Abstracts. 2016;34(15_suppl):7526.
85. Giuliano AE, Hunt K, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance). ASCO Meeting Abstracts. 2016;34(15_suppl):1007.
86. Goff LW, Lowery MA, Jordan E, Wang R, Bocobo AG, Chou JF, et al. Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis. ASCO Meeting Abstracts. 2016;34(15_suppl):e15636.
87. Goldman JW, Soria J-C, Wakelee HA, Camidge DR, Gadgeel SM, Yu HA, et al. Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2016;34(15_suppl):9045.

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

88. Gonzalez-Martin A, Backes FJ, Baumann KH, Chase DM, Fehr MK, Coleman RL, et al. A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS5606.
89. Goss PE, Ingle JN, Pritchard KI, Muss H, Gralow J, Gelmon KA, et al. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):LBA1.
90. Gounder MM, Bauer TM, Schwartz GK, Masters T, Carvajal RD, Song S, et al. A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas. ASCO Meeting Abstracts. 2016;34(15_suppl):2581.
91. Gounder MM, Wagner AJ, Somaiah N, Riedel RF, Schwartz GK, Attia S, et al. The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLs). ASCO Meeting Abstracts. 2016;34(15_suppl):TPS11072.
92. Grisham RN, Chiang S, Shen R, Murali R, Shu CA, Levine DA, et al. Characterization of actionable somatic alterations in microdissected gynecologic carcinosarcomas. ASCO Meeting Abstracts. 2016;34(15_suppl):5594.
93. Grisham RN, Giri DD, Iasonos A, Zhou Q, Girshman J, McGrath SP, et al. Phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two or three prior therapies. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS5602.
94. Grommes C, Kaley TJ, Nolan C, Omuro AMP, Wolfe J, Mellinghoff IK, et al. Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). ASCO Meeting Abstracts. 2016;34(15_suppl):2046.
95. Gucaip A, Proverbs-Singh TA, Corben A, Moynahan ME, Patil S, Boyle LA, et al. Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC). ASCO Meeting Abstracts. 2016;34(15_suppl):TPS1103.
96. Hamilton EP, Wang JS-Z, Falchook G, Jones SF, Cook C, Mugundu G, et al. A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):5562.
97. Hamlin PA, Flinn I, Wagner-Johnston N, Burger J, Michelson G, Pandey A, et al. Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies-- Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing. ASCO Meeting Abstracts. 2016;34(15_suppl):7557.
98. Harding JJ, Heins ZJ, Connell LC, Soumerai T, Kemeny NE, Jarnagin WR, et al. Identification of potentially actionable molecular alterations in advanced hepatocellular carcinoma (HCC). ASCO Meeting Abstracts. 2016;34(15_suppl):e15635.
99. Harrison DJ, Parisi MT, Shulkin BL, Chi Y-Y, Anderson JR, Mi X, et al. 18F 2Fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) response to predict event-free survival (EFS) in intermediate risk (IR) or high risk (HR) rhabdomyosarcoma (RMS): A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG). ASCO Meeting Abstracts. 2016;34(15_suppl):10549.
100. Harshman LC, Gray KP, Polacek L, Taplin M-E, Choudhury AD, Pomerantz MM, et al. An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel. ASCO Meeting Abstracts. 2016;34(15_suppl):e16509.

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

101. Hellmann MD, Gettinger SN, Goldman JW, Brahmer JR, Borghaei H, Chow LQ, et al. CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. ASCO Meeting Abstracts. 2016;34(15_suppl):3001.
102. Herath DH, Wilson-Ing D, Ramos E, Morstyn G. Assessing the natural language processing capabilities of IBM Watson for oncology using real Australian lung cancer cases. ASCO Meeting Abstracts. 2016;34(15_suppl):e18229.
103. Higginson DS, Damerla R, Scher ED, Gutinov SI, Thompson C, Cleary C, et al. HPV cell free DNA as a marker of response to chemoradiation for HPV-positive oropharyngeal cancers. ASCO Meeting Abstracts. 2016;34(15_suppl):6083.
104. Ho AL, Sherman EJ, Baxi SS, Haque S, Ni A, Antonescu CR, et al. Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma. ASCO Meeting Abstracts. 2016;34(15_suppl):6096.
105. Hodi FS, Postow MA, Chesney JA, Pavlick AC, Robert C, Grossmann KF, et al. Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069). ASCO Meeting Abstracts. 2016;34(15_suppl):9518.
106. Huh WK, Dizon DS, Powell MA, Leath CA, Landrum LM, Tanner E, et al. ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage I of the phase II GOG/NRG0265 study. ASCO Meeting Abstracts. 2016;34(15_suppl):5516.
107. Hui R, Gandhi L, Carcereny Costa E, Felip E, Ahn M-J, Eder JP, et al. Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). ASCO Meeting Abstracts. 2016;34(15_suppl):9026.
108. Hutson TE, Dutcus CE, Ren M, Baig MA, Fishman MN. Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts. 2016;34(15_suppl):4553.
109. Hyman DM, Rasco DW, Infante JR, Liu JF, Welkowsky E, Thai DL, et al. Preliminary results from the first in human study of activin-A inhibitor, STM434, in patients with granulosa cell ovarian cancer and other advanced solid tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):5536.
110. Hyman DM, Tran B, Corral Jaime J, Garralda E, Machiels J-PH, Schellens JHM, et al. Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):2500.
111. Ilson DH, Tabernero J, Shitara K, Winkler R, Naseri Moaddeli A, Ding C, et al. TAGS, a randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care vs placebo plus best supportive care in patients with metastatic gastric cancer refractory to standard treatments. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS4141.
112. Infante JR, Ahlers CM, Hodi FS, Postel-Vinay S, Schellens JHM, Heymach J, et al. ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS3107.
113. Infante JR, Hansen AR, Pishvaian MJ, Chow LQM, McArthur GA, Bauer TM, et al. A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):101.
114. Innocenti F, Owzar K, Jiang C, Sibley A, Mulkey F, Carey LA, et al. A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503. ASCO Meeting Abstracts. 2016;34(15_suppl):538.
115. Isakoff SJ, Saura C, Calvo I, Gil Gil MJ, Patt DA, Morales Murillo S, et al. FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS1105.

116. Iyengar NM, Smyth LM, Jochelson MS, Lake D, Gucalp A, Dickler MN, et al. Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-Positive metastatic breast cancer (MBC) after prior HP- or TDM/P-based therapy. ASCO Meeting Abstracts. 2016;34(15_suppl):611.

117. Iyer G, Balar AV, Milowsky MI, Huang WC, Woods M, Donat SM, et al. Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC). ASCO Meeting Abstracts. 2016;34(15_suppl):5011.

118. Janelins MC, Peppone LJ, Heckler CE, Kamen CS, Mohile SG, Magnuson A, et al. Longitudinal trajectory of cancer-related cognitive impairment up to six-months post-chemotherapy: A nationwide NCORP study in 839 breast cancer patients and non-cancer controls. ASCO Meeting Abstracts. 2016;34(15_suppl):10139.

119. Janjigian YY, Bendell JC, Calvo E, Kim JW, Ascierto PA, Sharma P, et al. CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). ASCO Meeting Abstracts. 2016;34(15_suppl):4010.

120. Janjigian YY, Sanchez-Vega F, Tuvy Y, Bouvier N, Riches JC, Margolis M, et al. Emergence of RTK/RAS/PI3K pathway alterations in trastuzumab-refractory HER2-positive esophagogastric (EG) tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):11608.

121. Jhaveri KL, Bedard PL, Cejalvo JM, Hart LL, Juric D, Kelly K, et al. Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS11621.

122. Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Iltu R, et al. Overall survival in patients with glioblastoma before and after bevacizumab approval. ASCO Meeting Abstracts. 2016;34(15_suppl):2062.

123. Johnson ML, Adjei AA, Ramalingam SS, Janne PA, Dominguez G, Gabrilovich D, et al. Preliminary results of ENCORE 601, a phase 1b/2, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2016;34(15_suppl):e20659.

124. Jordan E, Barron D, Schultz N, Chakravarty D, Kris MG, Rudin CM, et al. Next generation sequencing (NGS) in lung adenocarcinoma (LA) as a guide to treatment selection. ASCO Meeting Abstracts. 2016;34(15_suppl):9084.

125. Jordan E, Lowery MA, Ptashkin R, Zehir A, Berger MF, Maynard H, et al. Genomic profiling of pancreas ductal adenocarcinoma (PDA), actionability, and correlation with clinical phenotype. ASCO Meeting Abstracts. 2016;34(15_suppl):4127.

126. Kalinsky K, Lee SJ, Rubin KM, Lawrence DP, Iafrate AJ, Borger DR, et al. A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas: A trial of the ECOG-ACRIN Cancer Research Group (E2607). ASCO Meeting Abstracts. 2016;34(15_suppl):9501.

127. Kamat AM, Bellmunt J, Choueiri TK, Nam K, De Santis M, Dreicer R, et al. KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). ASCO Meeting Abstracts. 2016;34(15_suppl):TPS4576.

128. Katz SJ, Morrow M, Hawley ST, Jagsi R. Impact of 1st surgeon recommendation against CPM on patient treatment experiences and satisfaction. ASCO Meeting Abstracts. 2016;34(15_suppl):6570.

129. Kaufman H, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial. ASCO Meeting Abstracts. 2016;34(15_suppl):9508.

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

130. Kelly CM, Janjigian YY, Kelsen DP, Capanu M, Chou JF, Ilson DH, et al. Retrospective review of subsequent treatments (tx) for esophagogastric adenocarcinomas (EGA) refractory to FOLFOX. ASCO Meeting Abstracts. 2016;34(15_suppl):e15556.
131. Kerns SL, Fung C, Williams A, Abu Zaid MI, Sesso HD, Monahan P, et al. Cumulative burden of morbidity (CBM) among testicular cancer survivors (TCS) in the Platinum study. ASCO Meeting Abstracts. 2016;34(15_suppl):10089.
132. Khan H, Hall J, Hakimi AA, Pradhan K, Huang H, Cytryn L, et al. Genomic complexity and prognosis of renal medullary carcinoma. ASCO Meeting Abstracts. 2016;34(15_suppl):1544.
133. Khasraw M, Mukaro VR, West L, White K, Rippey E, Brandt C, et al. Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):e12515.
134. King TA, Lyman J, Gonen M, Reyes S, Hwang E-SS, Rugo HS, et al. A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). ASCO Meeting Abstracts. 2016;34(15_suppl):1006.
135. Klepin HD, Sun C-L, Smith DD, Elias R, Trevino KM, Bryant AL, et al. Predictors of unplanned hospitalizations among older adults receiving cancer chemotherapy. ASCO Meeting Abstracts. 2016;34(15_suppl):10057.
136. Klotz A, Seo S, Alickaj A. Management of febrile neutropenia in the observation unit of a cancer hospital. ASCO Meeting Abstracts. 2016;34(15_suppl):e18120.
137. Koon HB, Shepard DR, Merghoub T, Schaer DA, Sirard CA, Wolchok JD. First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):3017.
138. Kushner BH, Modak S, LaQuaglia MP, Wolden SL, Basu EM, Roberts SS, et al. Event-free survival (EFS) and overall survival (OS) of MYCN-amplified stage 2/3 neuroblastoma with or without autologous stem-cell transplantation (ASCT). ASCO Meeting Abstracts. 2016;34(15_suppl):10553.
139. Lacouture ME, Konner JA, Stevens J, Brouwer S, Narain NR, Ye R, et al. Topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Efficacy findings from a phase I safety study. ASCO Meeting Abstracts. 2016;34(15_suppl):2564.
140. Lacy S, Hutmacher MM, Yang B, Motzer RJ, Escudier BJ, Powles T, et al. Population pharmacokinetic (PopPK) and exposure-response (ER) modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma (RCC) in the phase 3 METEOR study. ASCO Meeting Abstracts. 2016;34(15_suppl):2565.
141. Larkin JMG, Ribas A, Flaherty K, McArthur GA, Ascierto PA, Dreno B, et al. Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) {+/-} cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. ASCO Meeting Abstracts. 2016;34(15_suppl):9536.
142. Lee C-H, Motzer RJ, Hoetker A, Akin O, Molina AM, Gold TM, et al. Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma. ASCO Meeting Abstracts. 2016;34(15_suppl):e16109.
143. Lee C-H, Wei E, Lee W, Chen Y, Mano R, Hakimi AA, et al. Genomic and metabolic characterization of succinate dehydrogenase B deficient renal cell carcinoma. ASCO Meeting Abstracts. 2016;34(15_suppl):e16102.
144. Leeman JE, Li J-G, Venigalla P, Zumsteg ZS, McBride SM, Boyle J, et al. Comparison of outcomes following recurrence or metastasis in HPV+ and HPV- oropharyngeal carcinoma treated with definitive chemoradiation using IMRT. ASCO Meeting Abstracts. 2016;34(15_suppl):6063.

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

145. Leeman JE, Li J-G, Venigalla P, Zumsteg ZS, McBride SM, Boyle J, et al. Natural history following recurrence after definitive locoregional treatment in 1000+ cases of locally advanced head and neck squamous cell carcinoma. ASCO Meeting Abstracts. 2016;34(15_suppl):6062.
146. Leitaio MM, Sonoda Y, Gardner GJ, Zivanovic O, Abu-Rustum N, Tseng J. Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival. ASCO Meeting Abstracts. 2016;34(15_suppl):5525.
147. Leitaio MM, Sonoda Y, Gardner GJ, Zivanovic O, Abu-Rustum N, Tseng J. Fertility-sparing surgery in stage IA2 cervical cancer: Associated factors and long-term survival. ASCO Meeting Abstracts. 2016;34(15_suppl):e17012.
148. Lemery SJ, Mailankody S, Kazandjian D, Smit M-AD, Blumenthal GM, Kim T, et al. Food and Drug Administration analysis of 1332 single patient and emergency use expanded access (compassionate use) requests for patients with cancer over a duration of three years (2012-2014). ASCO Meeting Abstracts. 2016;34(15_suppl):6523.
149. LeVasseur N, Clemons MJ, Mazzarello S, Vandermeer L, Jones L, Joy AA, et al. Optimal weight control strategies in cancer patients: A systematic review. ASCO Meeting Abstracts. 2016;34(15_suppl):10109.
150. Levine J, Whitton J, Leisenring WM, Green DM, Ginsberg JP, Stovall M, et al. Nonsurgical premature menopause (NSPM) in the Childhood Cancer Survivor Study (CCSS): Prevalence, risk factors, and reproductive outcomes. ASCO Meeting Abstracts. 2016;34(15_suppl):10504.
151. Lewin JH, Vis DJ, Voest EE, Liao R, Nederlof PM, Conley BA, et al. Determining barriers to effective data sharing in cancer genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey. ASCO Meeting Abstracts. 2016;34(15_suppl):11502.
152. Li BT, Zheng T, Ni A, Hellmann MD, Jordan E, Barron D, et al. Identifying HER2 mutation, amplification, and HER2 protein overexpression as therapeutic targets in lung cancers. ASCO Meeting Abstracts. 2016;34(15_suppl):e20666.
153. Li D, Dickler MN, McCall LM, Hahn OM, Hudis CA, Cohen HJ, et al. Identifying risk factors for toxicity in patients (Pts) with hormone-receptor positive (HR+) advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study. ASCO Meeting Abstracts. 2016;34(15_suppl):10047.
154. Lieu CH, Sheneman D, Finch JL, Davis SL, Leong S, Weekes CD, et al. Incidence of colorectal cancer among young adults in the state of Colorado. ASCO Meeting Abstracts. 2016;34(15_suppl):3585.
155. Lin X, Kaley TJ, Pentsova E, DeAngelis LM, Daras M, Gavrilovic IT, et al. Multicenter Phase IB trial of carboxyamidotriazole orotate (CTO) combined with temozolomide (TMZ) for recurrent glioblastoma (GBM) and other malignant gliomas (MG). ASCO Meeting Abstracts. 2016;34(15_suppl):2064.
156. Linker A, Roper N, Yang A, Korenstein D. Impact of industry funding and collaboration in oncology RCTs. ASCO Meeting Abstracts. 2016;34(15_suppl):6592.
157. Lipitz Snyderman AN, Classen D, Pfister DG, Killen A, Epstein AS, Anderson CB, et al. A patient safety approach to assessing adverse events in oncology: Results from CHARM (Cancer Harm) study. ASCO Meeting Abstracts. 2016;34(15_suppl):6601.
158. Liu D, Abbosh P, Miao D, Boyd ME, Hoffman-Censits JH, Iyer G, et al. Genomic evolution in muscle-invasive bladder cancer resistant to neoadjuvant chemotherapy. ASCO Meeting Abstracts. 2016;34(15_suppl):4518.
159. Lok BH, Zong J, Gutinov SI, Cai X, Deselm C, Romesser PB, et al. Proton radiotherapy for incurable recurrent or metastatic cancers of the head and neck by the RTOG 8502 hypofractionated palliative schedule. ASCO Meeting Abstracts. 2016;34(15_suppl):e21699.
160. Lorente D, Olmos D, Mateo J, Zafeiriou Z, Rescigno P, Bianchini D, et al. Circulating tumor cell (CTC) rise and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) with low baseline CTC counts. ASCO Meeting Abstracts. 2016;34(15_suppl):5042.

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

161. Lowery MA, Capanu M, Glassman DC, Covington CM, Gluskin J, Brenner R, et al. Phase 1B trial of ADI-PEG 20 (A) plus nab-Paclitaxel (nab-P) and gemcitabine (gem) in subjects with advanced pancreatic cancer (APC). ASCO Meeting Abstracts. 2016;34(15_suppl):e15756.
162. Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Kemeny NE, et al. Comprehensive molecular profiling and analysis of mutual exclusivity of genetic aberrations (MEGA) of intra- and extrahepatic cholangiocarcinomas (IHC and EHC) evaluation of prognostic features and potential targets for intervention. ASCO Meeting Abstracts. 2016;34(15_suppl):4088.
163. Mackall C, D'Angelo SP, Cristea MC, Odunsi K, Norry E, Pandite L, et al. Cytokine release syndrome (CRS) in patients treated with NY-ESO-1c259 TCR. ASCO Meeting Abstracts. 2016;34(15_suppl):3040.
164. Mackall C, D'Angelo SP, Grupp SA, Odunsi K, Cristea MC, Linette GP, et al. Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS3101.
165. Mailankody S, Korde N, Roschewski MJ, Christofferson A, Boateng M, Zhang Y, et al. Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients. ASCO Meeting Abstracts. 2016;34(15_suppl):8003.
166. Mao JJ, Hugo A, Yang J, Li SQ. Preference among non-white cancer patients for mobile devices and social media to learn about supportive services. ASCO Meeting Abstracts. 2016;34(15_suppl):e21686.
167. Marinovich ML, Azizi L, Macaskill P, Irwig L, Morrow M, Solin LJ, et al. The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: A meta-analysis. ASCO Meeting Abstracts. 2016;34(15_suppl):1020.
168. Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini MG, et al. Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR). ASCO Meeting Abstracts. 2016;34(15_suppl):7005.
169. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke JJ, et al. Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):4502.
170. Matthaiou C, Renfro LA, Papamichael D, Yothers G, Saltz L, Van Cutsem E, et al. Validity of Adjuvant! Online in elderly patients with stage III colon cancer based on 2,794 patients from the ACCENT database. ASCO Meeting Abstracts. 2016;34(15_suppl):3620.
171. Mauro MJ, McGarry L, Yang M, Lustgarten S, Huang H. Characteristics of ponatinib (PON) therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) patients (pts) in real-world (RW) clinical practice compared to the PACE trial. ASCO Meeting Abstracts. 2016;34(15_suppl):e18514.
172. Mauro MJ, McGarry L, Yang M, Lustgarten S, Huang H. Comparison of PACE clinical trial versus real-world (RW) ponatinib (PON) prescribing and duration of therapy (DOT) in US chronic-phase chronic myeloid leukemia (CP-CML) patients (pts). ASCO Meeting Abstracts. 2016;34(15_suppl):e18540.
173. McAlpine JN, McConechy M, Hoang L, Leung S, Nakonechny Q, Lum A, et al. A clinically applicable molecular-based classification for endometrial cancers. ASCO Meeting Abstracts. 2016;34(15_suppl):5518.
174. McArthur HL, Page DB, Proverbs-Singh TA, Solomon SB, Hudis CA, Norton L, et al. Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS3097.
175. McBride RB, Patel VG, Lorduy AC, Castillo-Martin M, Cha EK, Berger MF, et al. Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs). ASCO Meeting Abstracts. 2016;34(15_suppl):4538.

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

176. McCabe MS, Boekhout AH, Thom B, Corcoran S, Adsuar R, Oeffinger KC. Evaluation of nurse practitioner-led survivorship care. ASCO Meeting Abstracts. 2016;34(15_suppl):10081.
177. McDermott DF, Motzer RJ, Atkins MB, Plimack ER, Sznol M, George S, et al. Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. ASCO Meeting Abstracts. 2016;34(15_suppl):4507.
178. Menzies AM, Johnson DB, Ramanujam S, Atkinson V, Wong ANM, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI). ASCO Meeting Abstracts. 2016;34(15_suppl):9515.
179. Meric-Bernstam F, Tannir NM, Mier JW, DeMichele A, Telli ML, Fan AC, et al. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). ASCO Meeting Abstracts. 2016;34(15_suppl):4568.
180. Merlini G, Liedtke M, Landau HJ, Comenzo RL, Sanchowala V, Weiss BM, et al. The PRONTO amyloidosis study: A randomized, double-blind, placebo-controlled, global, phase 2b study of NEOD001 in previously treated subjects with light chain amyloidosis and persistent cardiac dysfunction. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS8073.
181. Middleton MR, Steven NM, Evans TJ, Infante JR, Sznol M, Mulatero C, et al. Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma. ASCO Meeting Abstracts. 2016;34(15_suppl):3016.
182. Mita MM, Becerra C, Richards DA, Mita AC, Shagisultanova E, Osborne CRC, et al. Phase 1b study of WNT inhibitor vantiactumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC). ASCO Meeting Abstracts. 2016;34(15_suppl):2516.
183. Modak S, Kushner BH, Kramer K, Leyco S, Basu EM, Roberts SS, et al. Phase II study of the combination of bevacizumab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma (NB). ASCO Meeting Abstracts. 2016;34(15_suppl):10554.
184. Moore KN, Martin LP, Matulonis UA, Konner JA, Seward SM, Bauer TM, et al. IMG853 (mirvetuximab soravtansine), a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts). ASCO Meeting Abstracts. 2016;34(15_suppl):5567.
185. Morris MJ, Lorient Y, Sweeney C, Fizazi K, Ryan CJ, Shevrin DH, et al. Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases. ASCO Meeting Abstracts. 2016;34(15_suppl):5075.
186. Morris MJ, Petrylak DP, Sartor AO, Vogelzang NJ, Groaning M, Ejadi S, et al. Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC). ASCO Meeting Abstracts. 2016;34(15_suppl):2586.
187. Motzer RJ, Sharma P, Escudier BJ, McDermott DF, George S, Srinivas S, et al. Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study. ASCO Meeting Abstracts. 2016;34(15_suppl):4552.
188. Moynahan ME, Sung P, Chen D, He W, Samoil A, You D, et al. Correlation of PIK3CA mutations in cell-free DNA (cfDNA) and efficacy of everolimus (EVE) in metastatic breast cancer: Results from BOLERO-2. ASCO Meeting Abstracts. 2016;34(15_suppl):519.
189. Munhoz RR, Lefkowitz RA, Kuk D, Dickson MA, D'Angelo SP, Keohan ML, et al. Efficacy of sorafenib in patients with desmoid-type fibromatosis. ASCO Meeting Abstracts. 2016;34(15_suppl):11065.
190. Munhoz RR, Shoushtari AN, Kuk D, Ott PA, Johnson DB, Tsai KK, et al. Clinical activity of anti-programmed death-1 (PD-1) agents in acral and mucosal melanoma. ASCO Meeting Abstracts. 2016;34(15_suppl):9516.

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

191. Munster PN, Mahipal A, Nemunaitis JJ, Mita MM, Paz-Ares LG, Massard C, et al. Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers. ASCO Meeting Abstracts. 2016;34(15_suppl):2505.
192. Naing A, Papadopoulos KP, Infante JR, Wong DJL, Autio KA, Ott PA, et al. Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1. ASCO Meeting Abstracts. 2016;34(15_suppl):3018.
193. Navi BB, Reiner AS, Kamel H, Okin PM, Iadecola C, Elkind MSV, et al. Risk of arterial thromboembolism in patients with colorectal cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):1572.
194. Necchi A, Sonpavde G, Lo Vullo S, Bamias A, Crabb SJ, Harshman LC, et al. The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination chemotherapy (CT). ASCO Meeting Abstracts. 2016;34(15_suppl):e16026.
195. Needle MN, Hutson TE, Motzer RJ. The effect of geography and the availability of second-line therapy on overall survival in a one-way crossover design study in renal cell carcinoma. ASCO Meeting Abstracts. 2016;34(15_suppl):e16120.
196. Nelson P, Mateo J, Beltran H, De Sarkar N, Elemento O, Rubin MA, et al. Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):5009.
197. O'Cearbhaill RE, McMeekin DS, Mantia-Smaldone G, Gunderson C, Sabbatini P, Cattaruzza F, et al. Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in recurrent platinum-sensitive ovarian cancer (OC). ASCO Meeting Abstracts. 2016;34(15_suppl):2515.
198. Oeffinger KC, Ford J, Moskowitz CS, Chou JF, Henderson TO, Hudson MM, et al. The EMPOWER study: Promoting breast cancer screening--A randomized controlled trial (RCT) in the Childhood Cancer Survivor Study (CCSS). ASCO Meeting Abstracts. 2016;34(15_suppl):10506.
199. Offit K, Schrader KA, Maxwell KN, Vijai J, Hart S, Thomas T, et al. Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing. ASCO Meeting Abstracts. 2016;34(15_suppl):1515.
200. Oh WK, Tombal BF, Delacruz A, Tomlinson B, Vella Ripley A, Drudge-Coates L, et al. Recognizing symptom burden in advanced prostate cancer: A global patient and caregiver survey. ASCO Meeting Abstracts. 2016;34(15_suppl):10124.
201. Omuro AMP, Beal K, McNeill KA, Thomas AA, Lin X, Kaley TJ, et al. Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM). ASCO Meeting Abstracts. 2016;34(15_suppl):2060.
202. O'Reilly EM, Mahalingam D, Roach JM, Miller PJ, Rosano ME, Krause S, et al. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Updated phase 1 results. ASCO Meeting Abstracts. 2016;34(15_suppl):4117.
203. O'Reilly EM, Oh D-Y, Lee MA, Dhani N, Armstrong J, Belli R, et al. A phase 2, open-label, multicenter study of durvalumab (MEDI4736) {+/-} tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS4150.
204. Paik PK, Eng J, Perez L, Ritter E, Ni A, Ng KK, et al. A phase I trial of certolizumab plus chemotherapy in patients with stage IV lung adenocarcinomas. ASCO Meeting Abstracts. 2016;34(15_suppl):9080.
205. Pal SK, Rosenberg JE, Keam B, Wolf J, Berger R, Dittrich C, et al. Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

- advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations. ASCO Meeting Abstracts. 2016;34(15_suppl):4517.
206. Papadopoulos KP, Naing A, Infante JR, Autio KA, Ott PA, Wong DJL, et al. Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):3082.
207. Park JH, Riviere I, Wang X, Purdon T, Sadelain M, Brentjens RJ. Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL. ASCO Meeting Abstracts. 2016;34(15_suppl):7003.
208. Parkinson CA, Gale D, Piskorz A, Hodgkin C, Biggs H, Addley H, et al. Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):e23040.
209. Patel MR, Fakih M, Olszanski AJ, Lockhart AC, Drilon AE, Fu S, et al. A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):2574.
210. Patel VG, McBride RB, Lorduy AC, Castillo-Martin M, Cha EK, Berger MF, et al. Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC). ASCO Meeting Abstracts. 2016;34(15_suppl):e16002.
211. Phillips AA, Fields P, Hermine O, Ramos JC, Beltran BE, Pereira J, et al. A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator's choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) adult T-cell leukemia-lymphoma (ATL). ASCO Meeting Abstracts. 2016;34(15_suppl):7501.
212. Phillips AA, Horwitz SM, Taylor GP, Humphrey JS, Tobinai K, Ishida T, et al. Differences between Japan and rest of world (ROW) in disease presentation and outcome of previously treated adult t-cell leukemia-lymphoma (ATL) using therapy with a monoclonal antibody to CCR4, mogamulizumab (moga). ASCO Meeting Abstracts. 2016;34(15_suppl):e19056.
213. Picardo SL, Teo M, Abdul Jalil KI, Naqvi SY, Morris PG, Breathnach OS, et al. Correlation between platelet/lymphocyte ratio, neutrophil/lymphocyte ratio and response to neoadjuvant chemoradiation therapy in rectal cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):e15140.
214. Pietanza MC, Krug LM, Waqar SN, Dowlati A, Hann CL, Chiappori A, et al. A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs). ASCO Meeting Abstracts. 2016;34(15_suppl):8512.
215. Pietzak EJ, Assel M, Tennenbaum DM, Becerra M, Feldman DR, Bajorin DF, et al. The role for resection of post-chemotherapy residual liver masses in the management of non-seminomatous germ cell tumor. ASCO Meeting Abstracts. 2016;34(15_suppl):e16047.
216. Pietzak EJ, Bagrodia A, Li Q, Al-Ahmadie H, Herr HW, Funt S, et al. Differences in somatic DNA damage repair (DDR) gene alterations between primary and secondary muscle invasive bladder cancer (MIBC). ASCO Meeting Abstracts. 2016;34(15_suppl):4519.
217. Plitas G, Wu K, Carlson J, Cimaglia N, Morrow M, Rudensky AY, et al. Phase I/II study of mogamulizumab, an anti-CCR4 antibody targeting regulatory T cells in advanced cancer patients. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS3098.
218. Pomerantz M, Wang XV, Kantoff PW, Xie W, Kohli M, Lee G-SM, et al. Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa). ASCO Meeting Abstracts. 2016;34(15_suppl):1540.
219. Postow MA, Kuk D, Adamow M, Carrera C, Wong P, Curran MA, et al. Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab + ipilimumab compared to ipilimumab alone. ASCO Meeting Abstracts. 2016;34(15_suppl):3073.

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

220. Powles T, Motzer RJ, Escudier BJ, Pal SK, Kollmannsberger CK, Pikiel J, et al. Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC). ASCO Meeting Abstracts. 2016;34(15_suppl):4557.
221. Prados M, Kuhn JG, Colman H, Cloughesy TF, Chang SM, Butowski NA, et al. Precision medicine in recurrent glioblastoma: A feasibility trial conducted by the Ivy Foundation Early Phase Clinical Trials Consortium. ASCO Meeting Abstracts. 2016;34(15_suppl):2031.
222. Prockop S, Doubrovina E, Baxi SS, Escobedo V, Suser S, Szenes V, et al. Treatment of EBV+ nasopharyngeal carcinoma with banked EBV-specific cytotoxic T cells. ASCO Meeting Abstracts. 2016;34(15_suppl):3012.
223. Raj NP, Soumerai T, Valentino E, Hechtman JF, Berger MF, Reidy DL. Next-generation sequencing (NGS) in advanced well differentiated pancreatic neuroendocrine tumors (WD pNETs): A study using MSK-IMPACT. ASCO Meeting Abstracts. 2016;34(15_suppl):e15661.
224. Rathkopf DE, Slovin SF, Autio KA, Delacruz A, Shelkey G, Pisano K, et al. A Phase II Study of the Dual mTOR Inhibitor MLN0128 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). ASCO Meeting Abstracts. 2016;34(15_suppl):e16529.
225. Razavi P, Cecchi F, Ross DS, Middha S, Zehir A, Arcila ME, et al. Use of next generation sequencing and quantitative mass spectrometry to determine HER2 status. ASCO Meeting Abstracts. 2016;34(15_suppl):e23237.
226. Reardon DA, De Groot JF, Colman H, Jordan JT, Daras M, Clarke JL, et al. Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM). ASCO Meeting Abstracts. 2016;34(15_suppl):2010.
227. Reardon DA, Kaley TJ, Dietrich J, Lim M, Dunn GP, Gan HK, et al. Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM). ASCO Meeting Abstracts. 2016;34(15_suppl):TPS2080.
228. Reardon DA, Sampson JH, Sahebjam S, Lim M, Baehring JM, Vlahovic G, et al. Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143. ASCO Meeting Abstracts. 2016;34(15_suppl):2014.
229. Reidy DL, Kulke MH, Wolin EM, Singh S, Ferone D, Mirakhur B, et al. Safety and efficacy of lanreotide depot/autogel (LAN) in patients with lung NETs: The randomized, double-blind, placebo (PBO)-controlled phase III SPINET study. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS8580.
230. Richter JR, Martin TG, Vij R, Cole C, Atanackovic D, Zonder JA, et al. Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM). ASCO Meeting Abstracts. 2016;34(15_suppl):8005.
231. Ricigiliano M, Cooper B, Ocean AJ, Tiriack H, Tuveson DA, Yu KH, et al. Expression levels of aldehyde dehydrogenase 1A1 (ALDH1A1) in circulating tumor and invasive cells (CTICs) as a biomarker for drug resistance and disulfiram in pancreatic adenocarcinoma (PDAC). ASCO Meeting Abstracts. 2016;34(15_suppl):e15755.
232. Riely GJ, Jordan E, Kim HR, Yu HA, Berger MF, Solit DB, et al. Association of outcomes and co-occurring genomic alterations in patients with KRAS-mutant non-small cell lung cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):9019.
233. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. ASCO Meeting Abstracts. 2016;34(15_suppl):9503.
234. Rodriguez-Galindo C, Pappo AS, Krailo MD, Pashankar F, Monteiro Caran EM, Hicks J, et al. Treatment of childhood adrenocortical carcinoma (ACC) with surgery plus retroperitoneal lymph node

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

- dissection (RPLND) and multiagent chemotherapy: Results of the Childrens Oncology Group ARAR0332 protocol. ASCO Meeting Abstracts. 2016;34(15_suppl):10515.
235. Rose TL, Ladoire S, Crehange G, Galsky MD, Rosenberg JE, Bellmunt J, et al. Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC). ASCO Meeting Abstracts. 2016;34(15_suppl):4536.
236. Rosenberg JE, Heath EI, Van Veldhuizen PJ, Merchan JR, Lang JM, Ruether JD, et al. Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC). ASCO Meeting Abstracts. 2016;34(15_suppl):4533.
237. Rosenberg JE, Petrylak DP, Van Der Heijden MS, Necchi A, O'Donnell PH, Loriot Y, et al. PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210). ASCO Meeting Abstracts. 2016;34(15_suppl):104.
238. Rozeznal JM, Ang C, Donovan M, Bangi E, Yeykal C, Cagan RL, et al. Clinical outcomes in genetically targeted cancer treatment. ASCO Meeting Abstracts. 2016;34(15_suppl):e23127.
239. Rozeznal JM, Posner MR, Ang C, Bangi E, Yeykal C, Cagan RL, et al. Transgenic drosophila as a drug-screening platform in colorectal cancer and medullary thyroid cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):e23164.
240. Rudin CM, Pietanza MC, Bauer TM, Spigel DR, Ready N, Morgensztern D, et al. Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). ASCO Meeting Abstracts. 2016;34(15_suppl):LBA8505.
241. Rusch VW, Tan KS, Ghanie A, Arcila ME, Travis WD, Jones DR, et al. Next generation sequencing (NGS) in resectable non-small cell lung cancer (NSCLC): Therapeutic implications. ASCO Meeting Abstracts. 2016;34(15_suppl):8541.
242. Sabbatini P, Chen L-m, Lucci JA, Behbakht K, Spirtos NM, Muller C, et al. A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission. ASCO Meeting Abstracts. 2016;34(15_suppl):5517.
243. Sahin IH, Turkekul M, Capanu M, Askan G, McMahon B, Yu KH, et al. Do pancreatic cancer (PDA) stem cell markers predict biologic behavior? ASCO Meeting Abstracts. 2016;34(15_suppl):4112.
244. Salz T, Brown P, Zabor EC, Dalton SO, Raghunathan NJ, Matasar MJ, et al. Pre-cancer cardiovascular risk factors and anthracycline-related cardiotoxicity among non-Hodgkin lymphoma survivors. ASCO Meeting Abstracts. 2016;34(15_suppl):e19031.
245. Sampson JH, Omuro AMP, Preusser M, Lim M, Butowski NA, Cloughesy TF, et al. A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS2079.
246. Sanford NN, Chen M-H, Loffredo MJ, Renshaw AA, Kantoff PW, D'Amico AV. Duration of the anti-androgen in men undergoing six months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death. ASCO Meeting Abstracts. 2016;34(15_suppl):5070.
247. Sapienza LG, Gomes MJL, Calsavara VF, Leitao MM, Baiocchi G. Does para-aortic irradiation reduce the risk of distant metastasis in cervical cancer? A systematic review and meta-analysis of randomized clinical trials. ASCO Meeting Abstracts. 2016;34(15_suppl):e17013.
248. Saura C, De Azambuja E, Oliveira M, Dubsy PC, Zardavas D, Fesl C, et al. LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS613.

249. Scher HI, Graf R, Schreiber NA, McLaughlin B, Lu D, Louw J, et al. AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy. ASCO Meeting Abstracts. 2016;34(15_suppl):5013.

250. Scher HI, Jendrisak A, Graf R, Schreiber NA, McLaughlin B, Greene S, et al. CTC phenotype classifier to identify mCRPC patients (pts) with high genomic instability CTCs and to predict failure of androgen receptor signaling (AR Tx) and taxane (T) systemic therapies. ASCO Meeting Abstracts. 2016;34(15_suppl):5044.

251. Segal NH, Kemeny NE, Cercek A, Reidy DL, Raasch PJ, Warren P, et al. Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients. ASCO Meeting Abstracts. 2016;34(15_suppl):3539.

252. Seiwert TY, Weiss J, Baxi SS, Ahn M-J, Fayette J, Gillison ML, et al. A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) {+/-} tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS6101.

253. Sequist LV, Anderson IC, Demars N, Felip E, Harb WA, Huber RM, et al. A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2016;34(15_suppl):TPS9110.

254. Shahrokni A, Sun C, Tew WP, Mohile SG, Owusu C, Klepin HD, et al. Complex association between social support and chemotherapy-related toxicities in older cancer patients. ASCO Meeting Abstracts. 2016;34(15_suppl):10036.

255. Shahrokni A, Vickers AJ, Mahmoudzadeh S, Korc-Grodzicki B. Assessing the clinical feasibility of electronic Rapid Fitness Assessment (eRFA): A novel geriatric assessment tool for the oncology setting. ASCO Meeting Abstracts. 2016;34(15_suppl):10011.

256. Sharma P, Bono P, Kim JW, Spiliopoulou P, Calvo E, Pillai RN, et al. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. ASCO Meeting Abstracts. 2016;34(15_suppl):4501.

257. Sherman EJ, Romesser PB, Ho AL, Baxi SS, Riaz N, McBride SM, et al. Radiation therapy and low dose doxorubicin in thyroid cancer: A phase II study. ASCO Meeting Abstracts. 2016;34(15_suppl):6100.

258. Shoushtari AN, Kudchadkar RR, Panageas K, Murthy RK, Jung M, Shah R, et al. A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma. ASCO Meeting Abstracts. 2016;34(15_suppl):9511.

259. Shoushtari AN, Navid-Azarbaijani P, Friedman CF, Panageas K, Postow MA, Callahan MK, et al. Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP). ASCO Meeting Abstracts. 2016;34(15_suppl):9554.

260. Slotkin EK, Magnan HD, Meyers PA, Chou AJ, Ambati SR, Wexler LH. Off-label use of bevacizumab in relapsed and refractory pediatric sarcoma patients: The Memorial Sloan Kettering Cancer Center Experience. ASCO Meeting Abstracts. 2016;34(15_suppl):10569.

261. Slovin SF, Knudsen KE, Carbone E, Showunmi A, Hullings M, Morris MJ, et al. Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). ASCO Meeting Abstracts. 2016;34(15_suppl):TPS5093.

262. Smyth LM, Reichel JB, Tang J, Patel JAA, Meng F, Selcuklu SD, et al. Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363). ASCO Meeting Abstracts. 2016;34(15_suppl):11500.

263. Soff GA, Parameswaran R, Mantha S, Miao Y, Mones JV. Romiplostim management of chemotherapy-induced thrombocytopenia. ASCO Meeting Abstracts. 2016;34(15_suppl):10134.

264. Somwar R, Smith R, Hayashi T, Ishizawa K, Snyder Charen A, Khodos I, et al. MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers. ASCO Meeting Abstracts. 2016;34(15_suppl):9068.

265. Soumerai JD, Barrientos JC, Hallek M, Kipps TJ, Jones JA, Stilgenbauer S, et al. An evaluation of the chronic lymphocytic leukemia (CLL) international prognostic index as a prognostic tool in patients with relapsed/refractory CLL in idelalisib phase 3 randomized studies. ASCO Meeting Abstracts. 2016;34(15_suppl):7513.

266. Suzuki M, Cheung IY, Cheung N-KV. Idiotype network induced by anti-GD2 immunotherapy is associated with long-term survival in patients with neuroblastoma. ASCO Meeting Abstracts. 2016;34(15_suppl):10570.

267. Sweeney C, Xie W, Regan MM, Nakabayashi M, Buyse ME, Clarke NW, et al. Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP). ASCO Meeting Abstracts. 2016;34(15_suppl):5023.

268. Tabernero J, Geel RV, Guren TK, Yaeger RD, Spreafico A, Faris JE, et al. Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFM CRC). ASCO Meeting Abstracts. 2016;34(15_suppl):3544.

269. Tallman MS, Feingold JM, Spira AI, Rizzieri D, Atallah EL, Stock W, et al. A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS7071.

270. Tallman MS, Knight RD, Glasmacher AG, Dohner H, on behalf of the IDHENTIFY Study Investigators Group. Phase III randomized, open-label study comparing the efficacy and safety of AG-221 vs conventional care regimens (CCR) in older patients with advanced acute myeloid leukemia (AML) with isocitrate dehydrogenase (IDH)-2 mutations in relapse or refractory to multiple prior treatments: the IDHENTIFY trial. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS7074.

271. Tan DS-W, Yang JC-H, Leigh NB, Riely GJ, Sequist LV, Felip E, et al. Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. ASCO Meeting Abstracts. 2016;34(15_suppl):9044.

272. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, et al. Phase I trial combining ipilimumab + high dose stereotactic radiation: Results and serum immune correlates. ASCO Meeting Abstracts. 2016;34(15_suppl):3022.

273. Tap WD, Mahoney MR, Jaslowski AJ, Horvath LE, Schwartz GK. A Phase I/Randomized Phase II Study of MLN0128 v.s Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma: Alliance A091304. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS11073.

274. Tarlock K, He J, Zhong S, Ries RE, Bailey M, Morley S, et al. Distinct age-associated genomic profiles in acute myeloid leukemia (AML) using FoundationOne heme. ASCO Meeting Abstracts. 2016;34(15_suppl):7041.

275. Tawbi HA-H, Burgess MA, Crowley J, Van Tine BA, Hu J, Schuetz S, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028--A multicenter phase II study. ASCO Meeting Abstracts. 2016;34(15_suppl):11006.

276. Teo M, Zabor EC, Iyer G, Bambury R, Boyd ME, Rosenberg JE. Genomic landscape of defective DNA damage response and repair mechanisms (DDR) across cancer types. ASCO Meeting Abstracts. 2016;34(15_suppl):e23219.

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

277. Tolcher AW, Hong DS, Sullivan RJ, Mier JW, Shapiro G, Pearlberg J, et al. IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K- γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS3111.
278. Traina TA, Plitas G, Reis-Filho JS, Morris EA, Hughes M, Sung JS, et al. Pilot trial of an implantable microdevice for In Vivo drug sensitivity testing in patients with early stage, triple negative breast cancer receiving neoadjuvant therapy. ASCO Meeting Abstracts. 2016;34(15_suppl):TPS1101.
279. Tran C, Hamilton JG, Lincoln A, Corines M, Musinsky J, Gaddam P, et al. Feasibility and long-term utility of a psychosocial support group for patients with Lynch syndrome. ASCO Meeting Abstracts. 2016;34(15_suppl):e21545.
280. Trigo Perez JM, Brummelen EV, Levchenko E, Domine M, Garrido Lopez P, Kindler HL, et al. Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM). ASCO Meeting Abstracts. 2016;34(15_suppl):8557.
281. Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, et al. Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM). ASCO Meeting Abstracts. 2016;34(15_suppl):9507.
282. Tseng J, Sonoda Y, Gardner GJ, Zivanovic O, Abu-Rustum N, Leitao MM. Long-term oncologic outcomes of fertility-sparing surgery in young women with stage IB1 cervical cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):e17010.
283. Tseng J, Sonoda Y, Gardner GJ, Zivanovic O, Abu-Rustum N, Leitao MM. Stage IA2 cervical cancer: Long-term outcomes with less radical as opposed to more radical surgical management. ASCO Meeting Abstracts. 2016;34(15_suppl):e17011.
284. Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O'Neil BH, et al. Impact of primary (1^o) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). ASCO Meeting Abstracts. 2016;34(15_suppl):3504.
285. Vij R, Lendvai N, Martin TG, Baz RC, Campana F, Mazuir F, et al. A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts. ASCO Meeting Abstracts. 2016;34(15_suppl):8009.
286. Voss MH, Chen D, Marker M, Knox J, Hsieh J, Voi M, et al. Baseline lactate dehydrogenase (LDH) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with everolimus (EVE) versus sunitinib (SUN): Predictive biomarker analysis from the RECORD-3 trial. ASCO Meeting Abstracts. 2016;34(15_suppl):e16118.
287. Wakelee HA, Gadgeel SM, Goldman JW, Reckamp KL, Karlovich CA, Melnikova V, et al. Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. ASCO Meeting Abstracts. 2016;34(15_suppl):9001.
288. Walsh MF, Gaddam P, Digiovanni L, Balmana J, Dolinsky JS, Sittler T, et al. Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants. ASCO Meeting Abstracts. 2016;34(15_suppl):1518.
289. Walsh MF, Musinsky J, Harlan Fleischut M, Kennedy J, Lincoln A, Stadler ZK, et al. The heritability of retinoblastoma: An institutional review. ASCO Meeting Abstracts. 2016;34(15_suppl):1591.
290. Wang X, Sun C, Hageman L, Barnett K, Desai S, Hawkins DS, et al. Combined clinical and genetic risk prediction of central nervous system subsequent neoplasms (CNS SNs) in childhood cancer survivors (CCS): A report from the COG ALTE03N1 study. ASCO Meeting Abstracts. 2016;34(15_suppl):10511.
291. Wheeler HE, Frisina RD, Gamazon ER, El Charif O, Feldman DR, Hamilton RJ, et al. Genome-wide association study (GWAS) of cisplatin-related hearing loss in testicular cancer survivors (TCS) to reveal

Memorial Sloan Kettering ASCO Meeting Abstracts 2016

associated variant in Wolfram syndrome 1 (WFS1) gene. ASCO Meeting Abstracts. 2016;34(15_suppl):10015.

292. Wierda WG, Coutre S, Flinn I, Gopal AK, O'Brien SM, Salles GA, et al. Management of transaminase elevations in patients receiving idelalisib. ASCO Meeting Abstracts. 2016;34(15_suppl):7532.

293. Wise D, Louw J, Krupa R, Schreiber NA, Sawyers CL, Dittamore RV, et al. Detection of glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) from patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). ASCO Meeting Abstracts. 2016;34(15_suppl):5046.

294. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). ASCO Meeting Abstracts. 2016;34(15_suppl):9505.

295. Wu CS-Y, Shi Q, Tomsic J, Meyers JP, Frankel WL, Timmers CD, et al. Deletions in HSP110 T17 and patient prognosis in stage III microsatellite instable (MSI) colon cancers: Findings from CALGB 89803 and NCCTG N0147. ASCO Meeting Abstracts. 2016;34(15_suppl):e15148.

296. Younes A, Santoro A, Zinzani PL, Timmerman J, Ansell SM, Armand P, et al. Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)--A phase 2 study. ASCO Meeting Abstracts. 2016;34(15_suppl):7535.

297. Yu HA, Jordan E, Ni A, Feldman D, Rodriguez C, Kim HR, et al. Concurrent genetic alterations identified by next-generation sequencing in pre-treatment, metastatic EGFR-mutant lung cancers. ASCO Meeting Abstracts. 2016;34(15_suppl):9053.

298. Yu HA, Spira AI, Horn L, Weiss J, West HJ, Giaccone G, et al. Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study. ASCO Meeting Abstracts. 2016;34(15_suppl):9050.

299. Yu KH, Ricigiliano M, O'Reilly EM, Lowery MA, Cooper B, Covington CM. Breast cancer resistance protein (ABCG2) as a potential biomarker for gemcitabine and nab-paclitaxel sensitivity. ASCO Meeting Abstracts. 2016;34(15_suppl):4129.

300. Zauderer MG, Dao T, Rusch VW, Ginsberg MS, Tsao AS, Panageas K, et al. Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy. ASCO Meeting Abstracts. 2016;34(15_suppl):8519.

301. Zehir A, Coombs CC, Devlin S, Kishtagari A, Hyman DM, Solit DB, et al. Prevalence of clonal hematopoiesis in patients with advanced cancer. ASCO Meeting Abstracts. 2016;34(15_suppl):1511.

302. Zelenetz AD, Mato AR, Robak T, Jones JA, Pagel JM, Barrientos JC, et al. Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody. ASCO Meeting Abstracts. 2016;34(15_suppl):7533.

303. Zelenetz AD, Salles GA, Mason KD, Casulo C, Le Gouill S, Sehn LH, et al. Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma. ASCO Meeting Abstracts. 2016;34(15_suppl):7566.

304. Zumsteg ZS, Lok BH, Ho AS, Riaz N, Shiao SL, McBride SM, et al. Toxicity and efficacy of concomitant chemoradiotherapy (CCRT) in elderly patients with oropharyngeal carcinoma (OPC) in the intensity modulated radiotherapy (IMRT) era. ASCO Meeting Abstracts. 2016;34(15_suppl):10050.